445479-01-6

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, [(1S,2R)-2-aminocyclopentyl]-, 1,1-dimethylethyl ester (9CI) is used as an intermediate in the synthesis of pharmaceutical drugs for its unique chemical properties and reactivity. It plays a crucial role in the development of new medications and therapies.
Used in Research Applications:
Carbamic acid, [(1S,2R)-2-aminocyclopentyl]-, 1,1-dimethylethyl ester (9CI) is also utilized in research settings for studying its chemical properties, reactivity, and potential applications in various fields. Researchers use it to explore new chemical reactions and develop innovative synthetic routes for the production of other valuable compounds.

Upstream product

• 181657-56-7 (1S,2S)-2-(benzyloxy)cyclopentanamine 
• 721395-14-8 (1S,2R)-2-(N-tert-butoxycarbonylamino)-1-azidocyclopentane 
• 365996-19-6 tert-butyl (+/-)-cis-(2-aminocyclopentyl)carbamate 
• 141-78-6 ethyl acetate 
• 93-92-5 1-phenylethyl acetate 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 125356-51-6 (1S,2S)-trans-2-azidocyclopentanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 756874-86-9 (1S,2S)-2-azido-cyclopentyl butyrate 
• 630386-07-1 (1S,2S)-2-(tert-butoxycarbonylamino)cyclopentyl methanesulfonate 
• 145106-43-0 (1S,2S)-trans-2-(tert-butoxycarbonylamino)cyclopentanol 
• 445479-00-5 (1S, 2S)-2-benzyloxy-cyclopentyl-carbamic acid tert-butyl ester 
• 756874-87-0 (1R,2S)-2-(N-tert-butoxycarbonylamino)-1-azidocyclopentane 
• 930-45-0 (1S,2S)-2-aminocyclopentanol 

Relevant academic research and scientific papers

CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Enzymatic dynamic kinetic resolution of (±)-cis-N-(Alkoxycarbonyl) cyclopentane-1,2-diamines based on spontaneous racemization

Lipase B from Candida antarctica is an excellent catalyst for the enantioselective acetylation of different (±)-cis-N-(alkoxycarbonyl) cyclopentane-1,2-diamines. Depending on the alkoxycarbonyl group, a simple kinetic resolution (Boc-derivative) or an interesting dynamic kinetic resolution (DKR with Cbz-, Alloc, and ethoxycarbonyl derivatives) has been developed. Racemization for the DKR occurred due to the N,N′ intramolecular migration of the alkoxycarbonyl group.

SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa

In the search of Factor Xa (FXa) inhibitors structurally different from the pyrazole-based series, we identified a viable series of enantiopure cis-(1R,2S)-cycloalkyldiamine derivatives as potent and selective inhibitors of FXa. Among them, cyclohexyldiam

CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS

The present application describes cyclic diamino compounds, derivatives thereof, and pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

cis-Cyclopentyl PNA (cpPNA) as constrained chiral PNA analogues: stereochemical dependence of DNA/RNA hybridization.

DNA/RNA hybridization studies of PNA-T oligomers with cis-(1S,2R/1R,2S)-cyclopentyl units in the backbone show stereochemistry dependent binding with RNA/DNA discrimination.

(1S,2R/1R,2S)-cis-cyclopentyl PNAs (cpPNAs) as constrained PNA analogues: Synthesis and evaluation of aeg-cpPNA chimera and stereopreferences in hybridization with DNA/RNA

Conformationally constrained chiral PNA analogues were designed on the basis of stereospecific imposition of a 1,2-cis-cyclopentyl moiety on an aminoethyl segment of aegPNA. It is known that the cyclopentane ring is a relatively flexible system in which the characteristic puckering dictates the pseudoaxial/pseudoequatorial dispositions of substituents. Hence, favorable torsional adjustments are possible to attain the necessary hybridization- competent conformations when the moiety is imposed on the conventional PNA backbone. The synthesis of the enantiomerically pure 1,2-cis-cyclopentyl PNA monomers (10a and 10b) was achieved by stereoselective enzymatic hydrolysis of a key intermediate ester 2. The chiral (1S,2R/1R,2S)-aminocyclopentylglycyl thymine monomers were incorporated into PNA oligomers at defined positions and through the entire sequence. Hybridization studies with complementary DNA and RNA sequences using UV-Tm measurements indicate that aeg-cpPNA. chimera form thermally more stable complexes than aegPNA with stereochemistry-dependent selective binding of cDNA/RNA. Differential gel shift retardation was observed on hybridization of aeg-cpPNAs with complementary DNA.

LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS

The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trysin-like serine proteases, specifically factor Xa.

ETHYLENEDIAMINE DERIVATIVES

The invention relates a compound represented by the formula (1):Q1-Q2-C(=O)-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.

1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS

The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Heterocycle derivatives and drugs

There is provided an excellent novel analgesic having an analgesic effect which is effective widely against a pain including a chronic pain or an allodynia accompanied with herpes zoster by acting on a nociceptin receptor. The present invention relates to a compound represented by the following formula: or a salt thereof. In the formula, X and Y are same or different and each represents a nitrogen atom or CH; R1 represents a hydrogen atom or alkyl and the like; A1 and A2 are same or different and each represents a single bond or a divalent aliphatic hydrocarbon group; Q represents a single bond, cycloalkylene group, phenylene group or divalent heterocyclic group; R2A, R2B, R2C and R2D are same or different and each represents a hydrogen atom, alkyl or phenyl; E represents a ethenylene group or —NRCO— (in which R is hydrogen or alkyl) and the like; R3 represents a phenyl group or a heterocyclic group; R4 and R5 are same or different and each represents a hydrogen atom, alkyl, alkoxy, aralkyloxy, halogen, nitro, hydroxy, alkoxycarbonyl, —NR6R7 (in which R6 and R7 are same or different and each represents a hydrogen atom or alkyl) and the like.